TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02029248

Intervention type: OTHER
Intervention: Quality of life questionnaire

Intervention type: OTHER
Intervention: Quality of life questionnaire

Intervention type: OTHER
Intervention: Quality of life questionnaire

Intervention type: OTHER
Intervention: Quality of life questionnaire
Study: NCT06022692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
Description: The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab (BeiGene, China) combined with PD-1 inhibitor
Description: The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
Study: NCT03515668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin 20 mg Tablet
Description: Single dose for all participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo with same appearance/taste
Study: NCT02455830

Intervention type: BIOLOGICAL
Intervention: Autologous cord blood cell therapy
Description: The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
Study: NCT00598000

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits.
Study: NCT02409277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Standard vs Intensive e-AT Intervention
Description: Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Standard vs Intensive e-AT Intervention
Description: Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
Study: NCT03024099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy once a week
Description: Hippotherapy once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy twice a week
Description: Hippotherapy twice a week
Study: NCT03307876

Intervention type: OTHER
Intervention: autologous PPP injection
Description: autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
Study: NCT04675008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
Study: NCT03016000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Just observation
Study: NCT03620877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized intervention
Description: Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
Study: NCT04333719

Intervention type: OTHER
Intervention: Type of sedations
Description: Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
Study: NCT02830685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTI with Acellular Dermal Matrix (CELLIS® Breast)
Description: After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)
Description: After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
Study: NCT02561468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00590772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg po each day (compared to placebo for 2 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 2 weeks
Study: NCT02823067

Intervention type: OTHER
Intervention: Blood sample
Description: One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
Study: NCT03078218

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
Study: NCT00459732

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: 25 mg of elemental zinc as zinc sulphate take once daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
Study: NCT01235741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide+Metreleptin
Description: Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
Study: NCT01833156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoistureMeterD
Description: measuring erythema size and the dielectric constant values
Study: NCT03284307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 20 participants will be administered Dexmedetomidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 20 participants will be administered Ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 20 participants will be administered Propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 20 participants will be administered Midazolam.
Study: NCT03188497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator
Study: NCT04491513

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography
Description: Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
Study: NCT02560545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20% THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20% THC
Study: NCT02122757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Cefaly tDCS
Description: 2mA during 30sec
Study: NCT03983317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System
Description: Transcutaneous electrical nerve stimulation
Study: NCT00632606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Study: NCT00580528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet Newsletters
Description: Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored print newsletters delivered via mail
Description: Tailored Newsletters with content to improve eating and activity to reduce blood pressure
Study: NCT04141904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG [Xeljanz]
Description: Tofacitinib 5mg capsules twice a day for 7-10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice a day for 7-10 days
Study: NCT01041963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril plus Losartan
Description: Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study: NCT01694498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: Desmopressin 25 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B. Desmopressin 50 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00588497

Intervention type: PROCEDURE
Intervention: Micro-insert hysteroscopic sterilization
Description: Placement of micro-inserts transcervically with the aid of a hysteroscope

Intervention type: RADIATION
Intervention: Plain abdominal Xray
Description: Performed immediately after micro-inserts placement and at 3 months

Intervention type: PROCEDURE
Intervention: Pelvic Ultrasound
Description: Performed immediately after micro-inserts placement and at 3 months.

Intervention type: RADIATION
Intervention: Hysterosalpingogram
Description: Performed 3 months after micro-inserts placement
Study: NCT00145158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 HLA-A2-restricted peptides and Montanide ISA51

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 HLA-A2-restricted peptides and CpG 7909
Study: NCT04870489

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin and CO2 laser
Description: Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Co2 laser
Description: After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
Study: NCT00790140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prosure
Description: This is an enteral tube feed with 125 kcals \& 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ensure Plus
Description: This is a standard enteral tube feed with 150 kcals \& 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
Study: NCT02942459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: 25 Weekly Hours of Music Therapy by an Educated Music Therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: 25 weekly Hours of Being Together with an unknown Care Staff Member
Study: NCT03800147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mutaflor Suspension (E. coli Nissle 1917)
Description: Inoculation of Mutaflor Suspension (E. coli Nissle 1917)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mutaflor Suspension (E. coli Nissle 1917)
Description: Inoculation of Mutaflor Suspension (E. coli Nissle 1917)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires
Study: NCT00689507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: monoclonal antibody
Study: NCT02146534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release fampridine
Description: pts will receive Fampyra 10 mg BID PO for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be taken PO BID
Study: NCT02873702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules.
Study: NCT00452816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Solutions Consulting approach
Description: Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention
Description: Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
Study: NCT04952948

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PILATES Training
Description: During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES Training
Description: During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
Study: NCT02749084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T reg DLI
Description: Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter.
Study: NCT03791957

Intervention type: OTHER
Intervention: Blood Haemoglobin
Description: Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood

Intervention type: OTHER
Intervention: Blood Haemoglobin
Description: Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood

Intervention type: OTHER
Intervention: Blood Haemoglobin
Description: Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
Study: NCT02637492

Intervention type: OTHER
Intervention: Collection of clinical signs and symptoms
Description: Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
Study: NCT00950859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (Cohort I)
Description: 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (Cohort II)
Description: 50 mg twice daily